Patients with Diffuse Large B-cell Lymphoma with indication for palliative radiotherapy are treated with low-dose radiation (2 x 2 Gy) to the symptomatic sites only. The primary endpoint of the study is the response rate and Quality of Life of the patients (QoL).
Response is planned at 21-day after completion of the treatment. Response assessment is based on the standard definitions of the World Health Organization using complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) as response assessment criteria. The efficacy of the treatment consisted of a reduction greater than 50% of the maximum diameter of the radiated mass (PR + CR). QoL is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 3.0 version questionnaire. The QLQ-C30 questionnaire is self administered to the patients at baseline and at 21 days after treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
2 x 2 Gy on symptomatic sites only
Centro di Riferimento Oncologico
Aviano, Pordenone, Italy
RECRUITINGResponse rate
Clinical response is defined as reduction \> 50% of maximum diameter of the radiated lesion
Time frame: Clinical response up to 21 days after treatment
Quality of life according to the EORTC QLQ-C30 questionnaire
Time frame: The QLQ-C30 questionnaire is administered at baseline and at 21 days after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.